THE STUDY OF AN INVESTIGATIONAL DRUG, REVUSIRAN (ALN-TTRSC), FOR THE TREATMENT OF TRANSTHYRETIN (TTR)-MEDIATED AMYLOIDOSIS IN PATIENTS WHOSE DISEASE HAS CONTINUED TO WORSEN FOLLOWING LIVER TRANSPLANT: